MAP3K5 and diabetic kidney disease: Previous animal-level studies have shown that inhibition of ASK1 can effectively reduce liver and kidney injury and fibrosis and is expected to be a possible target for the therapy of nonalcoholic steatohepatitis (NASH) [181] and diabetic kidney disease (DKD) [182] and other diseases.